These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

637 related items for PubMed ID: 15809483

  • 1. Radiation exposure of patients undergoing whole-body dual-modality 18F-FDG PET/CT examinations.
    Brix G, Lechel U, Glatting G, Ziegler SI, Münzing W, Müller SP, Beyer T.
    J Nucl Med; 2005 Apr; 46(4):608-13. PubMed ID: 15809483
    [Abstract] [Full Text] [Related]

  • 2. Technologist radiation exposure in routine clinical practice with 18F-FDG PET.
    Guillet B, Quentin P, Waultier S, Bourrelly M, Pisano P, Mundler O.
    J Nucl Med Technol; 2005 Sep; 33(3):175-9. PubMed ID: 16145226
    [Abstract] [Full Text] [Related]

  • 3. Radiation exposure of patients and personnel from a PET/CT procedure with 18F-FDG.
    Leide-Svegborn S.
    Radiat Prot Dosimetry; 2010 Sep; 139(1-3):208-13. PubMed ID: 20167792
    [Abstract] [Full Text] [Related]

  • 4. PET/CT and SPECT/CT dosimetry in children: the challenge to the pediatric imager.
    Gelfand MJ, Lemen LC.
    Semin Nucl Med; 2007 Sep; 37(5):391-8. PubMed ID: 17707244
    [Abstract] [Full Text] [Related]

  • 5. Doses to nuclear technicians in a dedicated PET/CT centre utilising 18F fluorodeoxyglucose (FDG).
    Seierstad T, Stranden E, Bjering K, Evensen M, Holt A, Michalsen HM, Wetteland O.
    Radiat Prot Dosimetry; 2007 Sep; 123(2):246-9. PubMed ID: 16987913
    [Abstract] [Full Text] [Related]

  • 6. Optimized contrast-enhanced CT protocols for diagnostic whole-body 18F-FDG PET/CT: technical aspects of single-phase versus multiphase CT imaging.
    Brechtel K, Klein M, Vogel M, Mueller M, Aschoff P, Beyer T, Eschmann SM, Bares R, Claussen CD, Pfannenberg AC.
    J Nucl Med; 2006 Mar; 47(3):470-6. PubMed ID: 16513616
    [Abstract] [Full Text] [Related]

  • 7. A Monte Carlo based method to estimate radiation dose from multidetector CT (MDCT): cylindrical and anthropomorphic phantoms.
    DeMarco JJ, Cagnon CH, Cody DD, Stevens DM, McCollough CH, O'Daniel J, McNitt-Gray MF.
    Phys Med Biol; 2005 Sep 07; 50(17):3989-4004. PubMed ID: 16177525
    [Abstract] [Full Text] [Related]

  • 8. Operational radiation safety for PET-CT, SPECT-CT, and cyclotron facilities.
    Zanzonico P, Dauer L, St Germain J.
    Health Phys; 2008 Nov 07; 95(5):554-70. PubMed ID: 18849690
    [Abstract] [Full Text] [Related]

  • 9. Weight-based, low-dose pediatric whole-body PET/CT protocols.
    Alessio AM, Kinahan PE, Manchanda V, Ghioni V, Aldape L, Parisi MT.
    J Nucl Med; 2009 Oct 07; 50(10):1570-7. PubMed ID: 19793734
    [Abstract] [Full Text] [Related]

  • 10. Feasibility of [18F]FDG-PET and coregistered CT on clinical target volume definition of advanced non-small cell lung cancer.
    Messa C, Ceresoli GL, Rizzo G, Artioli D, Cattaneo M, Castellone P, Gregorc V, Picchio M, Landoni C, Fazio F.
    Q J Nucl Med Mol Imaging; 2005 Sep 07; 49(3):259-66. PubMed ID: 16172572
    [Abstract] [Full Text] [Related]

  • 11. Role of whole body positron emission tomography/computed tomography scan with 18F-fluorodeoxyglucose in patients with biopsy proven tumor metastases from unknown primary site.
    Pelosi E, Pennone M, Deandreis D, Douroukas A, Mancini M, Bisi G.
    Q J Nucl Med Mol Imaging; 2006 Mar 07; 50(1):15-22. PubMed ID: 16557200
    [Abstract] [Full Text] [Related]

  • 12. Early detection of cancer recurrence: 18F-FDG PET/CT can make a difference in diagnosis and patient care.
    Israel O, Kuten A.
    J Nucl Med; 2007 Jan 07; 48 Suppl 1():28S-35S. PubMed ID: 17204718
    [Abstract] [Full Text] [Related]

  • 13. Impact of whole-body imaging on treatment decision to radio-frequency ablation in patients with malignant liver tumors: comparison of [18F]fluorodeoxyglucose-PET/computed tomography, PET and computed tomography.
    Kuehl H, Rosenbaum-Krumme S, Veit-Haibach P, Stergar H, Forsting M, Bockisch A, Antoch G.
    Nucl Med Commun; 2008 Jul 07; 29(7):599-606. PubMed ID: 18528181
    [Abstract] [Full Text] [Related]

  • 14. Monitoring cancer treatment with PET/CT: does it make a difference?
    Weber WA, Figlin R.
    J Nucl Med; 2007 Jan 07; 48 Suppl 1():36S-44S. PubMed ID: 17204719
    [Abstract] [Full Text] [Related]

  • 15. Whole-body radiation dosimetry of 2-[18F]Fluoro-A-85380 in human PET imaging studies.
    Obrzut SL, Koren AO, Mandelkern MA, Brody AL, Hoh CK, London ED.
    Nucl Med Biol; 2005 Nov 07; 32(8):869-74. PubMed ID: 16253812
    [Abstract] [Full Text] [Related]

  • 16. Integrating PET and PET/CT into the risk-adapted therapy of lymphoma.
    Kasamon YL, Jones RJ, Wahl RL.
    J Nucl Med; 2007 Jan 07; 48 Suppl 1():19S-27S. PubMed ID: 17204717
    [Abstract] [Full Text] [Related]

  • 17. PET/CT: dose-escalated image fusion?
    Brix G, Beyer T.
    Nuklearmedizin; 2005 Jan 07; 44 Suppl 1():S51-7. PubMed ID: 16395980
    [Abstract] [Full Text] [Related]

  • 18. Increased (18)F-fluorodeoxyglucose uptake in benign, nonphysiologic lesions found on whole-body positron emission tomography/computed tomography (PET/CT): accumulated data from four years of experience with PET/CT.
    Metser U, Even-Sapir E.
    Semin Nucl Med; 2007 May 07; 37(3):206-22. PubMed ID: 17418153
    [Abstract] [Full Text] [Related]

  • 19. 18F-FDG PET and CT/MRI in oral cavity squamous cell carcinoma: a prospective study of 124 patients with histologic correlation.
    Ng SH, Yen TC, Liao CT, Chang JT, Chan SC, Ko SF, Wang HM, Wong HF.
    J Nucl Med; 2005 Jul 07; 46(7):1136-43. PubMed ID: 16000282
    [Abstract] [Full Text] [Related]

  • 20. 18F-FDG PET/CT for staging of penile cancer.
    Scher B, Seitz M, Reiser M, Hungerhuber E, Hahn K, Tiling R, Herzog P, Reiser M, Schneede P, Dresel S.
    J Nucl Med; 2005 Sep 07; 46(9):1460-5. PubMed ID: 16157528
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 32.